Insilicos begins prospective heart attack study
Seattle, 14 September 2011 - Insilicos announced today that the Seattle life sciences company has begun enrolling clinical subjects in a diagnostic study to predict heart attacks up to two years before they occur.
The study will evaluate Insilicos’ PreClue diagnostic test by collecting blood samples from 400 persons who visit a Seattle-area emergency room with chest pain. Those who agree to participate in the study will provide a blood sample. The PreClue diagnostic will be used on the samples to predict each person’s risk of a heart attack.
“This prospective study is a milestone for PreClue and for Insilicos,” said Insilicos Chief Scientist Dr. Bryan Prazen. “PreClue has previously shown powerful results on banked samples. We’re now building on that work with this large study of a group of patients --patients who frankly need better information about the risks they face. The prospect of being able to help such people is exciting –as is the opportunity to create a valuable sample set.”
Insilicos is collaborating with researchers at the University of Washington in the study. The work is funded in part by the National Heart, Lung, a Blood Institute, a part of the National Institutes of Health.